Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 162 | $110,093,809 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 29 | 67.32 | 1,952 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 75 | 49.6 | 3,720 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 64 | 67.12 | 4,296 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 94 | 49.6 | 4,662 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 100 | 49.6 | 4,960 | D |
22 Feb 2023 20:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 21 Feb 2023 | Sale | 123 | 47.32 | 5,820 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 13 Mar 2023 | Sale | 258 | 44.14 | 11,388 | D |
22 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 21 Feb 2023 | Sale | 251 | 49.6 | 12,450 | D |
05 Feb 2024 18:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 02 Feb 2024 | Sale | 185 | 67.35 | 12,460 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 200 | 68.03 | 13,606 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 07 Mar 2024 | Sale | 220 | 66.81 | 14,698 | D |
13 Mar 2023 19:36 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 13 Mar 2023 | Sale | 346 | 44.29 | 15,324 | D |
28 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 28 Aug 2024 | Sale | 240 | 73.7 | 17,688 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 13 Mar 2023 | Sale | 423 | 44.05 | 18,633 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 288 | 70.15 | 20,203 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 300 | 68.33 | 20,499 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 300 | 68.54 | 20,562 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 306 | 67.33 | 20,603 | D |
27 Feb 2024 19:57 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 26 Feb 2024 | Sale | 299 | 69.6 | 20,810 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 13 Mar 2023 | Sale | 476 | 44.15 | 21,015 | D |
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 18 Jan 2024 | Sale | 320 | 66.25 | 21,200 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 392 | 70.13 | 27,491 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 643 | 47.23 | 30,369 | D |
22 Feb 2023 20:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 21 Feb 2023 | Sale | 635 | 48.93 | 31,071 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 800 | 47.2 | 37,760 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 800 | 47.32 | 37,856 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 806 | 48.63 | 39,196 | D |
27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 600 | 68.39 | 41,034 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 600 | 69.81 | 41,886 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 900 | 48.72 | 43,848 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 661 | 66.96 | 44,261 | D |
05 Feb 2024 18:13 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 02 Feb 2024 | Sale | 714 | 67.17 | 47,959 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 1,100 | 48.68 | 53,548 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 872 | 65.89 | 57,456 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 13 Mar 2023 | Sale | 1,412 | 44.08 | 62,241 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 1,100 | 66.54 | 73,194 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 10 Mar 2023 | Sale | 1,800 | 42.74 | 76,932 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Mar 2024 | Sale | 1,238 | 66.7 | 82,575 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 17 Feb 2023 | Sale | 1,689 | 50.59 | 85,447 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 1,313 | 66.86 | 87,787 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 1,307 | 71.18 | 93,032 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,312 | 71.02 | 93,178 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,400 | 69.38 | 97,132 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,400 | 70.16 | 98,224 | D |
12 Jan 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Jan 2024 | Sale | 1,486 | 67.8 | 100,751 | D |
22 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 21 Feb 2023 | Sale | 2,200 | 47.35 | 104,170 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 1,590 | 66.81 | 106,228 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 10 Mar 2023 | Sale | 2,500 | 42.52 | 106,300 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 1,729 | 65.92 | 113,976 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 10 Mar 2023 | Sale | 2,700 | 42.52 | 114,804 | D |
20 Jul 2023 17:47 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 17 Jul 2023 | Sale | 1,842 | 65 | 119,730 | D |
22 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 21 Feb 2023 | Sale | 2,502 | 48.7 | 121,847 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 2,179 | 65.06 | 141,766 | D |
22 Feb 2023 20:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 21 Feb 2023 | Sale | 3,140 | 46.61 | 146,355 | D |
23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 21 Aug 2024 | Sale | 1,900 | 77.9805 | 148,163 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 13 Mar 2023 | Sale | 3,335 | 45.1 | 150,408 | D |
05 Feb 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Feb 2024 | Sale | 2,320 | 66.69 | 154,721 | D |
04 Jan 2024 19:54 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Jan 2024 | Sale | 2,210 | 71.77 | 158,612 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 2,341 | 70.7 | 165,509 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 07 Mar 2024 | Sale | 2,722 | 66.86 | 181,993 | D |
27 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 24 Feb 2023 | Sale | 4,046 | 47.12 | 190,648 | D |
23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 21 Aug 2024 | Sale | 2,682 | 77.2139 | 207,088 | D |
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 16 Jan 2024 | Sale | 3,500 | 66.38 | 232,330 | D |
16 Jun 2023 17:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 14 Jun 2023 | Sale | 3,592 | 65.01 | 233,516 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 13 Mar 2023 | Sale | 5,324 | 44.97 | 239,420 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 07 Mar 2024 | Sale | 3,728 | 66.34 | 247,316 | D |
21 Dec 2022 16:06 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 19 Dec 2022 | Sale | 5,000 | 50.82 | 254,100 | D |
05 Feb 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 02 Feb 2024 | Sale | 3,847 | 67.49 | 259,634 | D |
08 Nov 2022 16:12 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 07 Nov 2022 | Sale | 5,000 | 52.1117 | 260,558 | D |
08 Nov 2022 16:12 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 07 Nov 2022 | Sale | 5,000 | 52.4929 | 262,464 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 4,128 | 65.9 | 272,035 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 4,303 | 65.11 | 280,168 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 4,059 | 69.56 | 282,344 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 10 Mar 2023 | Sale | 6,805 | 42.51 | 289,281 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 4,453 | 65.28 | 290,692 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 10 Mar 2023 | Sale | 6,750 | 43.5 | 293,625 | D |
30 Mar 2023 17:08 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 28 Mar 2023 | Sale | 5,421 | 54.86 | 297,396 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 4,475 | 66.47 | 297,453 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 07 Mar 2024 | Sale | 4,496 | 66.95 | 301,007 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 13 Mar 2023 | Sale | 6,868 | 44.99 | 308,991 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 6,673 | 46.55 | 310,628 | D |
13 Mar 2023 19:36 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 13 Mar 2023 | Sale | 6,998 | 45.08 | 315,470 | D |
23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 21 Aug 2024 | Sale | 4,297 | 76.2001 | 327,432 | D |
23 Aug 2024 18:00 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 22 Aug 2024 | Sale | 4,369 | 75.4697 | 329,727 | D |
05 Feb 2024 18:07 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 02 Feb 2024 | Sale | 4,956 | 66.67 | 330,417 | D |
25 Jun 2024 18:04 | ITCI | Intra-Cellular Therapies Inc | RIGGS RORY B | Director | 24 Jun 2024 | Sale | 4,462 | 75.57 | 337,193 | D |
27 Feb 2023 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 24 Feb 2023 | Sale | 7,455 | 47.03 | 350,609 | D |
03 Mar 2023 19:03 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 01 Mar 2023 | Sale | 7,241 | 50.01 | 362,122 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 5,282 | 69.47 | 366,941 | D |
27 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 24 Feb 2023 | Sale | 7,906 | 47.03 | 371,819 | D |
27 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 24 Feb 2023 | Sale | 7,906 | 47.14 | 372,689 | D |
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 16 Jan 2024 | Sale | 5,882 | 67.76 | 398,564 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Mar 2024 | Sale | 6,107 | 65.82 | 401,963 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 8,649 | 46.54 | 402,524 | D |
30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 29 Aug 2024 | Sale | 5,772 | 73.2451 | 422,771 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 07 Mar 2024 | Sale | 6,514 | 66.26 | 431,618 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 9,296 | 46.56 | 432,822 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 07 Mar 2024 | Sale | 6,618 | 66.93 | 442,943 | D |
30 Aug 2024 18:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman and CEO | 30 Aug 2024 | Sale | 6,193 | 73.3232 | 454,091 | D |
05 Feb 2024 18:07 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 02 Feb 2024 | Sale | 6,904 | 67.49 | 465,951 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)